Extended Data Table 1 Clinical and demographic baseline characteristics of all study cohorts

From: Twin study reveals non-heritable immune perturbations in multiple sclerosis

  1. Overview of baseline characteristics of the groups and cohorts analyzed in the present study.
  2. MS = Multiple Sclerosis; ALZ = Alemtuzumab; DMF = Dimethyl Fumarate; FTY = Fingolimod; GLAT = Glatiramer Acetate; IFN = beta Interferons; NAT = Natalizumab; TFM = Teriflunomide; f = female; m = male; RRMS = relapsing-remitting MS; SPMS = secondary progressive MS; PPMS = primary progressive MS; NA = not applicable; unk = unknown.
Back to article page